.png)
Agenzia Italiana del Farmaco
AIFA call for a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment - AIFA call for a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment
AIFA call for a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment
Italian Agency of Medicines (AIFA) promotes the grant of a clinical study on efficacy of monoclonal antibodies for COVID-19 treatment.
In order to verify whether monoclonal antibodies can represent a real therapeutic option in preventing the progression of COVID-19 in patients in an early stage of the disease, the Italian Medicines Agency (AIFA) deems it useful to promote and support a randomized clinical trial.
Study protocols should meet all the call requirements and should be drafted using the provided form.
The deadline for submission is 15 February 2021 at 12.00pm CET, by sending the documentation to: bandomonoclonali@aifa.gov.it
Any request for information should be sent to: bandomonoclonali@aifa.gov.it
Published on: 21 January 2021
Last updated on: 27 January 2021
Contacts
Via del Tritone, 181 00187 Roma
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR